GleamWall
中文EN

RKTO Rocket One Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1711786 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY2.2%
TTM EPS YoY40.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-152.0%
ROA-132.9%
ROIC (approx.)-1,024.5%
Asset turnover—

Leverage & solvency

Liabilities / assets14.3%
Debt / equity0.00x
Current ratio5.55x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.92x
Accruals ratio-10.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$35———————
R&D expense$1.12M$1.96M$1.52M$1.31M$1.63M$1.04M$1.96M$1.32M
SG&A expense$1.41M$1.88M$1.13M$1.29M$2.45M$1.16M$1.52M$1.06M
Operating income-$2.53M-$3.83M-$2.65M-$2.61M-$4.08M-$2.20M-$3.48M-$2.38M
Pretax income-$2.68M-$3.83M—-$2.62M-$4.11M-$2.20M——
Net income-$2.68M-$3.83M-$2.69M-$2.69M-$4.11M-$2.20M-$3.48M-$2.38M
EPS (basic)-0.11-0.19-0.17—-0.30-0.17-0.27—
EPS (diluted)-0.11-0.19-0.17—-0.30-0.17-0.27—
Weighted avg. shares (diluted)24.71M20.55M15.79M—13.79M13.18M12.73M—
Balance sheet
Cash & equivalents$6.02M$7.89M$4.05M$6.25M$7.85M$9.01M$11.32M$7.04M
Receivables$4,523———————
Current assets$6.86M$8.58M$4.86M$6.86M$8.92M$10.05M$12.29M$7.64M
Goodwill$590,794———————
Intangibles$208,846———————
Total assets$8.66M$9.58M$5.59M$7.60M$9.24M$10.11M$12.36M$7.71M
Current liabilities$1.24M$1.38M$1.43M$1.45M$1.01M$364,630$815,299$831,197
Total liabilities$1.24M$1.38M$1.43M$1.45M$1.01M$364,630$815,299$833,906
Shareholders' equity$7.42M$8.20M$4.16M$6.15M$8.23M$9.74M$11.54M$6.88M
Shares outstanding24.90M23.18M16.27M15.51M15.13M13.23M13.17M8.04M
Cash flow statement
Operating cash flow-$2.79M-$2.97M-$3.05M-$2.15M-$2.49M-$2.37M-$2.79M-$2.03M
Investing cash flow-$992,682$0$147,202$0————
Financing cash flow$1.90M$6.81M$701,484$550,138$1.63M$66,101$7.07M$1.06M
Stock-based compensation$123,137$677,079$0$0$1.13M$55,525$219,929$541

Free plan shows the latest 8 periods; Pro shows all 35 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.